

PHARMACIA CORP /DE/
Form 5
February 15, 2002

FORM 5

Check box if no longer subject to
Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).

Form 3 Holdings Reported

Form 4 Transactions Reported

OMB APPROVAL

OMB Number: 323
Expires: December 31
Estimated average bu
hours per response..

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of t
Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of

1. Name and Address of Reporting Person*

2. Issuer Name and Ticker

King, Gwendolyn S.

(Last) (First) (Middle)

3. I.R.S. Identification
Number of Reporting
Person, if an entity
(Voluntary)

100 Route 206 North

(Street)

Peapack, NJ 07977

(City) (State) (Zip)

6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X Director 10% Owner

Edgar Filing: PHARMACIA CORP /DE/ - Form 5

----- Officer (give
title below)

----- Other (specify
below)

7. Individual or Joint/Group Reporting
(check Applicable Line)

- X Form filed by One Reporting Person
--
-- Form filed by More than One Reporting Person
--

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans- action Date (Month/ Day/ Year)	3. Trans- action Code (Instr. 8)	4. Securities or Disposed (Instr. 3, Amount
Common (1)	04/17/2001	A	2,200

5. Amount of
Securities
Beneficially
Owned at
end of Issuer's
Fiscal Year
(Instr. 3 and 4)

6. Ownership
Form: Direct (D)
or Indirect (I)
(Instr. 4)

7. Nature of
Indirect
Beneficial
Ownership
(Instr. 4)

6,145(2)(3)

D

*If the form is filed by more than one reporting person, see

Edgar Filing: PHARMACIA CORP /DE/ - Form 5

instruction 4(b)(v).

(Over)
SEC 2270 (3-99)

Page 1 of 3

FORM 5 (continued)

King, Gwendolyn S. - December 2001

Table II - Derivative Securities Acquired, Disposed of, or
Beneficially Owned (e.g., puts, calls, warrants,
options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Con- version or Exercise Price of Derivative Security	3. Trans- action Date (Month/ Day/ Year)	4. Transac- tion Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Dat and (Mo
				(A) (D)	Dat Exe abl
Option (right to buy)	\$44.25				(4
Stock Equivalent Units	1-for-1				

7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned at End of Year	10. Ownership of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indir Benefici Ownersi (Instr.

Edgar Filing: PHARMACIA CORP /DE/ - Form 5

(Instr. 4)

Title	Amount or Number of Shares		
Common	11,818	11,818	D
Common	2,233	2,233 (5)	D

Explanation of Responses:

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations.

See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Don W. Schmitz	2/14/2002
-----	-----
** Signature of Reporting Person Don W. Schmitz, attorney-in-fact for Gwendolyn S. King	Date

Page 2
SEC 2270 (3-99)

Page 2 of 3

Pharmacia Corporation PHA

Form 5 - December 2001

King, Gwendolyn S.
100 Route 206 North

Edgar Filing: PHARMACIA CORP /DE/ - Form 5

Peapack, NJ 07977

Explanation of responses:

- (1) Deferred shares.
- (2) Includes 58 shares acquired through the reinvestment of dividends since last reported to the SEC.
- (3) Includes deferred shares and shares acquired through reinvested dividends.
- (4) Option is currently exercisable.
- (5) Share equivalents acquired through the Non-Employee Directors Deferred Compensation Plan, including share equivalents accrued through the reinvestment of dividends.

Page 3 of 3